McCollum Christoferson Group LLC Sells 62,644 Shares of Abbott Laboratories $ABT

Key Points

• McCollum Christoferson Group LLC reduced its Abbott Laboratories stake by 60.7%, selling 62,644 shares and retaining 40,581 shares valued at approximately $3.68 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Abbott exceeded quarterly expectations with $1.31 in EPS and $12.59 billion in revenue, while revenue rose 13% year over year. The company projects fiscal 2026 EPS of $5.45–$5.60, with analysts expecting $5.52.
• Wall Street maintains a generally favorable view, with a consensus “Moderate Buy” rating and a $118.17 price target; Abbott also declared a quarterly dividend of $0.63 per share, representing a 2.3% annualized yield.

McCollum Christoferson Group LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 60.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 40,581 shares of the healthcare product maker's stock after selling 62,644 shares during the quarter. McCollum Christoferson Group LLC's holdings in Abbott Laboratories were worth $3,682,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in ABT. Nia Impact Advisors LLC boosted its position in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock valued at $504,000 after buying an additional 79 shares during the period. Riggs Asset Managment Co. Inc. boosted its holdings in Abbott Laboratories by 9.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker's stock valued at $140,000 after acquiring an additional 88 shares during the period. GHP Investment Advisors Inc. grew its position in Abbott Laboratories by 0.3% during the 4th quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker's stock worth $3,685,000 after acquiring an additional 92 shares during the last quarter. Eley Financial Management Inc increased its stake in Abbott Laboratories by 0.9% in the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker's stock worth $1,355,000 after purchasing an additional 92 shares during the period. Finally, Copley Financial Group Inc. increased its stake in Abbott Laboratories by 2.1% in the 4th quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker's stock worth $556,000 after purchasing an additional 93 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Bank of America issues a Buy rating: The endorsement from Bank of America Securities adds to positive Wall Street sentiment and may support investor confidence in Abbott’s earnings and growth outlook. Abbott Laboratories Receives a Buy from Bank of America Securities
• Positive Sentiment: Abbott and Google expand glucose-monitoring partnership: Abbott will integrate Lingo glucose data with Google’s AI-driven consumer health tools. The companies also plan a large real-world metabolic-health study, potentially improving personalized coaching, supporting future Lingo features and increasing the commercial value of Abbott’s biowearable platform. Abbott Laboratories Ties Lingo Glucose Data to AI Health Tools
• Positive Sentiment: Potential cardiovascular innovation: Abbott’s ongoing PULSE study is evaluating early treatment for atrial fibrillation. Positive results could strengthen Abbott’s electrophysiology portfolio, although the study remains a longer-term catalyst and does not yet establish a commercial benefit. Early AF Treatment on Trial: What Abbott’s PULSE Study Could Mean for Investors
• Neutral Sentiment: Blood-donation campaign returns: Abbott and the Big Ten revived the “We Give Blood” campaign amid a U.S. blood shortage. The initiative enhances Abbott’s public profile and reinforces its healthcare mission, but it is unlikely to have a material near-term effect on earnings. Abbott and Big Ten Bring Back We Give Blood

Wall Street Analyst Weigh In

ABT has been the subject of a number of analyst reports. Mizuho dropped their price objective on Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating for the company in a research note on Friday, April 17th. Oppenheimer lowered their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Citigroup increased their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Benchmark cut their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Finally, Robert W. Baird started coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $118.17.

Abbott Laboratories Stock Performance

Shares of ABT opened at $110.92 on Thursday. The company has a 50-day simple moving average of $96.86 and a two-hundred day simple moving average of $99.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a market capitalization of $191.93 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.59. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business's revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's dividend payout ratio is 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source